You are here

Dermavant

With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line

With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line

Endpoints

clinical trials

Flag link:

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Phase 3 wins put Dermavant closer to filing Otezla rival tapinarof

Pharmaforum

clinical trials

Flag link:

Ramaswamy's Dermavant Updates $124 Million IPO Filing

Ramaswamy's Dermavant Updates $124 Million IPO Filing

CP Wire

Vivek Ramaswamy

Flag link:

Ramaswamy's Dermavant Updates $124 Million IPO Filing

Flag link:

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

BioCentury

Prevail Therapeutics

Akero Therapeutics

Flag link:

Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug

Dermavant inks $330M deal for GSK's phase 3-ready psoriasis drug

Fierce Biotech

atopic dermatitis

Flag link: